A new journal article on Hoosier Cancer Research Network’s GU07-122 study will appear in the October 2015 issue of Urologic Oncology. The study was designed to determine feasibility and safety of treatment with dasatinib administered orally once daily for 4 weeks duration prior to radical cystectomy for urothelial carcinoma of the bladder.

Highlights reported in the article include:

• Dasatinib, a Src inhibitor, was feasible as neoadjuvant therapy for bladder cancer.
• Overall, significant Src pathway inhibition was seen in tumor tissue.
• Cell proliferation and apoptosis were unaltered overall.
• Src inhibition appears ineffective in unselected bladder cancer patients.
• The neoadjuvant trial paradigm may complement drug development.

See abstract.

About Hoosier Cancer Research Network

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,600 subjects have participated in Hoosier Cancer Research Network clinical trials.